These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32078014)

  • 21. Preoperative vascular heterogeneity based on dynamic susceptibility contrast MRI in predicting spatial pattern of locally recurrent high-grade gliomas.
    Wang H; Zeng L; Wu H; Tian J; Xie H; Zhang L; Ran Q; Zhong P; Chen L; Yi L; Wang S
    Eur Radiol; 2024 Mar; 34(3):1982-1993. PubMed ID: 37658897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.
    Ding H; Huang Y; Li Z; Li S; Chen Q; Xie C; Zhong Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819877167. PubMed ID: 31564237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
    Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
    Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
    Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
    Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study.
    Del Mar Álvarez-Torres M; Juan-Albarracín J; Fuster-Garcia E; Bellvís-Bataller F; Lorente D; Reynés G; Font de Mora J; Aparici-Robles F; Botella C; Muñoz-Langa J; Faubel R; Asensio-Cuesta S; García-Ferrando GA; Chelebian E; Auger C; Pineda J; Rovira A; Oleaga L; Mollà-Olmos E; Revert AJ; Tshibanda L; Crisi G; Emblem KE; Martin D; Due-Tønnessen P; Meling TR; Filice S; Sáez C; García-Gómez JM
    J Magn Reson Imaging; 2020 May; 51(5):1478-1486. PubMed ID: 31654541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
    Patel SH; Batchala PP; Muttikkal TJE; Ferrante SS; Patrie JT; Fadul CE; Schiff D; Lopes MB; Jain R
    J Neurooncol; 2021 May; 152(3):523-531. PubMed ID: 33661425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI Features May Predict Molecular Features of Glioblastoma in
    Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
    AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels.
    Álvarez-Torres MDM; López-Cerdán A; Andreu Z; de la Iglesia Vayá M; Fuster-Garcia E; García-García F; García-Gómez JM
    NMR Biomed; 2023 Nov; 36(11):e5004. PubMed ID: 37482922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
    Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
    J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
    Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of IDH and TERTp mutations using dynamic susceptibility contrast MRI with deep learning in 162 gliomas.
    Buz-Yalug B; Turhan G; Cetin AI; Dindar SS; Danyeli AE; Yakicier C; Pamir MN; Özduman K; Dincer A; Ozturk-Isik E
    Eur J Radiol; 2024 Jan; 170():111257. PubMed ID: 38134710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
    Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
    Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.
    Park JE; Eun D; Kim HS; Lee DH; Jang RW; Kim N
    Sci Rep; 2021 May; 11(1):9912. PubMed ID: 33972663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.